Pharmaceuticals

GLP-1 Therapy Significantly Increases Visceral Adipose Tissue Metabolic Activity in Patients with Obesity, Obstructive Sleep Apnea

bexib
By bexib 0 Min Read

Findings from a study published in the Journal of the Obesity Society may significantly advance the understanding of GLP-1 analogues and their role in treating obesity.

You Might Also Like

FDA approves Lilly’s Xanla to treat early symptoms of Alzheimer’s disease

Pharma Pulse 6/17/24: Medicinal plants in modern pharmacy, dynamic pricing and more

Factors behind pharmacy closures and their long-term impact

Trial investigating fecal microbiota transplantation to treat rare liver disease

The rise of AI in pharmaceuticals

Share This Article
Previous Article Synthetic Lethality: Q&A with Oren Gilad, CEO of Aprea Therapeutics
Next Article Southeast Asia’s solar surge shows how dynamic trade execution must be
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Capella Hotel Group creates meaningful moments of tradition to celebrate Chinese New Year
Hospitality & Tourism
AI M&A deals expected to increase in 2025
Banking
Remember American Giant’s $12.98 Walmart T-shirt? They made money.
Manufacturing
What is a drafting machine?
Manufacturing